TY - JOUR
T1 - Docetaxel for treatment of solid tumours
T2 - A systematic review of clinical data
AU - Montero, Alberto
AU - Fossella, Frank
AU - Hortobagyi, Gabriel
AU - Valero, Vicente
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2005/4
Y1 - 2005/4
N2 - Docetaxel is a semisynthetic taxane, a class of anticancer agents that bind to β tubulin, thereby stabilising microtubules and inducing cell-cycle arrest and apoptosis. Docetaxel was first approved for the treatment of anthracycline-refractory metastatic breast cancer in the mid-1990s. Since then, several randomised trials have reported improved time-to-progression, overall survival, or both in metastatic breast cancer treated with single-agent docetaxel or docetaxel-based combination regimens. Data from two adjuvant trials have shown a survival benefit with the addition of docetaxel to standard anthracycline-based regimens in patients with high-risk early breast cancer. In four randomised studies, docetaxel improved survival in locally advanced or metastatic non-small-cell lung cancer. Moreover, two trials have shown that docetaxel combined with estramustine or corticosteroids improves survival in metastatic androgen-independent prostate cancer. Here, we review major randomised phase III trials with docetaxel in the treatment of solid malignant disease.
AB - Docetaxel is a semisynthetic taxane, a class of anticancer agents that bind to β tubulin, thereby stabilising microtubules and inducing cell-cycle arrest and apoptosis. Docetaxel was first approved for the treatment of anthracycline-refractory metastatic breast cancer in the mid-1990s. Since then, several randomised trials have reported improved time-to-progression, overall survival, or both in metastatic breast cancer treated with single-agent docetaxel or docetaxel-based combination regimens. Data from two adjuvant trials have shown a survival benefit with the addition of docetaxel to standard anthracycline-based regimens in patients with high-risk early breast cancer. In four randomised studies, docetaxel improved survival in locally advanced or metastatic non-small-cell lung cancer. Moreover, two trials have shown that docetaxel combined with estramustine or corticosteroids improves survival in metastatic androgen-independent prostate cancer. Here, we review major randomised phase III trials with docetaxel in the treatment of solid malignant disease.
UR - http://www.scopus.com/inward/record.url?scp=16244414000&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=16244414000&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(05)70094-2
DO - 10.1016/S1470-2045(05)70094-2
M3 - Review article
C2 - 15811618
AN - SCOPUS:16244414000
SN - 1470-2045
VL - 6
SP - 229
EP - 239
JO - Lancet Oncology
JF - Lancet Oncology
IS - 4
ER -